Neuraminidase inhibitors and single dose baloxavir are effective and safe in uncomplicated influenza: a meta-analysis of randomized controlled trials

References

• Burden of influenza [Internet]. Worldff Health Organization (WHO). [cited 2021 Feb 19]. Available from: https://www.euro.who.int/en/health-topics/communicable-diseases/influenza/seasonal-influenza/burden-of-influenza
   Google Scholar
• Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical practice guidelines By The infectious diseases society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenza. Clin Infect Dis. 2019;68(6):895–902. .
   PubMed Web of Science ®Google Scholar
• Tejada S, Campogiani L, Solé-Lleonart C, et al. Alternative regimens of neuraminidase inhibitors for therapy of hospitalized adults with influenza: a systematic review of randomized controlled trials. Adv Ther. 2020;37(6):2646–2666.
   PubMed Web of Science ®Google Scholar
• Ishaqui AA, Khan AH, Sulaiman SA, et al. Efficacy comparison of oseltamivir alone and oseltamivir-antibiotic combination for early resolution of symptoms of severe influenza-A and influenza-B hospitalized patients. Saudi Med J. 2020;41(9):1015–1021.
   PubMed Web of Science ®Google Scholar
• Ishaqui AA, Khan AH, Sulaiman SAS, et al. Assessment of efficacy of Oseltamivir-Azithromycin combination therapy in prevention of Influenza-A (H1N1)pdm09 infection complications and rapidity of symptoms relief. Expert Rev Respir Med. 2020;14(5):533–541.
   PubMed Web of Science ®Google Scholar
• Ishaqui A, Hayat Khan A, Sulaiman SAS, et al. Comparative efficacy assessment of antiviral alone and antiviral-antibiotic combination in prevention of influenza-B infection associated complications. Expert Rev Anti Infect Ther. 2021;5:1–9.
   Google Scholar
• Heo Y-A. Baloxavir: first global approval. Drugs. 2018;78(6):693–697.
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34. .
   PubMed Web of Science ®Google Scholar
• Falagas ME, Koletsi PK, Vouloumanou EK, et al. Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials. J Antimicrob Chemother. 2010;65(7):1330–1346.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;18:343:d5928.
   Google Scholar
• Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5(1):13.
   PubMedGoogle Scholar
• Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003 6;327(7414):557–560. .
   PubMed Web of Science ®Google Scholar
• Beigel JH, Manosuthi W, Beeler J, et al. Effect of oral oseltamivir on virological outcomes in low-risk adults with influenza: a randomized clinical trial. Clin Infect Dis. 2019;69(11):1903–1911.
   PubMedGoogle Scholar
• Lin J-T, Yu X-Z, Cui D-J, et al. A multicentre, randomized, controlled trial of oseltamivir in the treatment of influenza in a high-risk Chinese population. Curr Med Res Opin. 2006;22(1):75–82. .
   PubMed Web of Science ®Google Scholar
• Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000;355(9218):1845–1850. .
   PubMed Web of Science ®Google Scholar
• Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000;283(8):1016–1024. .
   PubMed Web of Science ®Google Scholar
• Puhakka T, Lehti H, Vainionpää R, et al. Zanamivir: a significant reduction in viral load during treatment in military conscripts with influenza. Scand J Infect Dis. 2003;35(1):52–58. .
   PubMed Web of Science ®Google Scholar
• Murphy KR, Eivindson A, Pauksens K, et al. Efficacy and safety of inhaled zanamivir for the treatment of influenza in patients with asthma or chronic obstructive pulmonary disease. Clin Drug Investig. 2000;20(5):337–349. .
   Web of Science ®Google Scholar
• Mäkelä MJ, Pauksens K, Rostila T, et al. Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study. J Infect. 2000;40(1):42–48. .
   PubMed Web of Science ®Google Scholar
• The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet. 1998;352(9144):1877–1881. .
   PubMed Web of Science ®Google Scholar
• Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 influenza study group. N Engl J Med. 1997;337(13):874–880. .
   PubMed Web of Science ®Google Scholar
• Whitley R, Laughlin A, Carson S, et al. Single dose peramivir for the treatment of acute seasonal influenza: integrated analysis of efficacy and safety from two placebo-controlled trials. Antivir Ther. 2015;20(7):709–719. .
   PubMed Web of Science ®Google Scholar
• Kohno S, Kida H, Mizuguchi M, et al., S-021812 Clinical Study Group. Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. Antimicrob Agents Chemother. 2010;54(11):4568–4574. .
   PubMed Web of Science ®Google Scholar
• Hayden FG, Sugaya N, Hirotsu N, et al. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N Engl J Med. 2018;379(10):913–923. .
   PubMed Web of Science ®Google Scholar
• Ison MG, Portsmouth S, Yoshida Y, et al. Early treatment with baloxavir marboxil in high-risk adolescent and adult outpatients with uncomplicated influenza (CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet Infect Dis. 2020; (10):1204–1214. DOI:10.1016/S1473-3099(20)30004-9.
   PubMed Web of Science ®Google Scholar
• Watanabe A, Ishida T, Hirotsu N, et al. Baloxavir marboxil in Japanese patients with seasonal influenza: dose response and virus type/subtype outcomes from a randomized phase 2 study. Antiviral Res. 2019;163:75–81.
   PubMed Web of Science ®Google Scholar
• Dawood FS, Jara J, Gonzalez R, et al. A randomized, double-blind, placebo-controlled trial evaluating the safety of early oseltamivir treatment among children 0-9 years of age hospitalized with influenza in El Salvador and Panama. Antiviral Res. 2016;133:85–94.
   PubMed Web of Science ®Google Scholar
• Heinonen S, Silvennoinen H, Lehtinen P, et al. Early oseltamivir treatment of influenza in children 1-3 years of age: a randomized controlled trial. Clin Infect Dis. 2010;51(8):887–894. .
   PubMed Web of Science ®Google Scholar
• Johnston SL, Ferrero F, Garcia ML, et al. Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma. Pediatr Infect Dis J. 2005;24(3):225–232.
   PubMed Web of Science ®Google Scholar
• Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001;20(2):127–133. .
   PubMed Web of Science ®Google Scholar
• Hedrick JA, Barzilai A, Behre U, et al. Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial. Pediatr Infect Dis J. 2000;19(5):410–417. .
   PubMed Web of Science ®Google Scholar
• De Jong MD, Ison MG, Monto AS, et al. Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients. Clin Infect Dis. 2014;59(12):e172–185. .
   PubMed Web of Science ®Google Scholar
• Fry AM, Goswami D, Nahar K, et al. Efficacy of oseltamivir treatment started within 5 days of symptom onset to reduce influenza illness duration and virus shedding in an urban setting in Bangladesh: a randomised placebo-controlled trial. Lancet Infect Dis. 2014;14(2):109–118. .
   PubMed Web of Science ®Google Scholar
• Taieb V, Ikeoka H, Ma -F-F, et al. A network meta-analysis of the efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors for the treatment of influenza in otherwise healthy patients. Curr Med Res Opin. 2019;35(8):1355–1364. .
   PubMed Web of Science ®Google Scholar
• Taieb V, Ikeoka H, Wojciechowski P, et al. Efficacy and safety of baloxavir marboxil versus neuraminidase inhibitors in the treatment of influenza virus infection in high-risk and uncomplicated patients - a Bayesian network meta-analysis. Curr Med Res Opin. 2020;9:1–20.
   Google Scholar
• Wang K, Shun‐Shin M, Gill P, et al. Neuraminidase inhibitors for preventing and treating influenza in children (published trials only. Cochrane Database Syst Rev. 2012;4:1–55.
   Google Scholar
• Hirotsu N, Sakaguchi H, Sato C, et al. Baloxavir Marboxil in Japanese pediatric patients with influenza: safety and clinical and virologic outcomes. Clin Infect Dis Off Publ Infect Dis Soc Am. 2020;71(4):971–981. .
   PubMed Web of Science ®Google Scholar
• Du Z, Nugent C, Galvani AP, et al. Modeling mitigation of influenza epidemics by baloxavir. Nat Commun. 2020;11(1):2750.
   PubMed Web of Science ®Google Scholar
• Takashita E, Daniels RS, Fujisaki S, et al. Global update on the susceptibilities of human influenza viruses to neuraminidase inhibitors and the cap-dependent endonuclease inhibitor baloxavir, 2017-2018. Antiviral Res. 2020;175:104718.
   PubMed Web of Science ®Google Scholar
• Lina B, Boucher C, Osterhaus A, et al. Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the influenza resistance information study. Influenza Other Respir Viruses. 2018;12(2):267–278. .
   PubMed Web of Science ®Google Scholar
• Uehara T, Hayden FG, Kawaguchi K, et al. Treatment-emergent influenza variant viruses with reduced baloxavir susceptibility: impact on clinical and virologic outcomes in uncomplicated influenza. J Infect Dis. 2020;221(3):346–355. .
   PubMed Web of Science ®Google Scholar
• Komeda T, Takazono T, Hosogaya N, et al. Comparison of hospitalization incidence in influenza outpatients treated with baloxavir marboxil or neuraminidase inhibitors: a health insurance claims database study. Clin Infect Dis Off Publ Infect Dis Soc Am. 2020. [Online ahead of print].
   Google Scholar
• Kumar D, Ison M, Mira J-P, et al. Combining baloxavir with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza: results from the global, randomised, phase 3 FLAGSTONE study. In: The seventh ESWI Influenza Conference. Valencia, Spain; 2020. ( Abstract ID: 152).
   Google Scholar
• Ikematsu H, Hayden FG, Kawaguchi K, et al. Baloxavir Marboxil for Prophylaxis against influenza in household contacts. N Engl J Med. 2020;383(4):309–320. .
   PubMed Web of Science ®Google Scholar